1. A Transplantable Syngeneic Allograft Mouse Model for Nongestational Choriocarcinoma of the Ovary
- Author
-
Nathan M Pate, Zoe Weaver Ohler, Lucy Lu, Melanie Gordon, Ludmila Szabova, and Baktiar O. Karim
- Subjects
endocrine system ,endocrine system diseases ,Mice, Transgenic ,Syncytiotrophoblasts ,Ovary ,Biology ,Malignancy ,Article ,Human chorionic gonadotropin ,Mice ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Animals ,reproductive and urinary physiology ,030304 developmental biology ,Ovarian Neoplasms ,0303 health sciences ,General Veterinary ,Choriocarcinoma ,Choriocarcinoma, Non-gestational ,Cancer ,Allografts ,medicine.disease ,female genital diseases and pregnancy complications ,Disease Models, Animal ,Serous fluid ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Genetically Engineered Mouse ,embryonic structures ,Cancer research ,Female ,Neoplasm Transplantation - Abstract
Nongestational choriocarcinoma is a rare malignancy in humans with poor prognosis. Naturally occurring choriocarcinoma is also rare in laboratory mice, and no genetic mouse model accurately recapitulates the features of this cancer. Here we report development of a genetically engineered mouse (GEM) model with alterations in Brca2, Trp53, and RB that develops ovarian tumors. Most of the ovarian tumors displayed histological characteristics of nongestational choriocarcinoma of the ovary (NGCO) (47%) with abundant syncytiotrophoblasts and cytotrophoblasts, positive immunolabeling for human chorionic gonadotropin, and positive periodic acid–Schiff reaction. The rest of the ovarian tumors were serous epithelial ovarian carcinoma (SEOC) (26%) or mixed tumors consisting of NGCO and SEOC (26%). We further established syngeneic orthotopic mouse models for NGCO by in vivo passaging of GEM tumors. These metastatic models provide a platform for evaluating new treatment strategies in preclinical studies aimed at improving outcomes in choriocarcinoma patients.
- Published
- 2019